TKO Group Holdings director Carrie Wheeler reported equity compensation activity, exercising 1,237 restricted stock units (RSUs) to acquire Class A common stock, increasing her direct holdings to 7,836 shares. She also received a new grant of 1,123 RSUs. Both the exercised and newly granted RSUs have specific vesting dates tied to the company's annual stockholder meetings.

TKO Group Holdings director Sonya E. Medina increased her equity stake by exercising 1,237 restricted stock units (RSUs) into Class A common stock and receiving a new grant of 1,123 RSUs. These transactions are part of her routine equity compensation, bringing her direct holdings to 4,937 shares. The newly granted RSUs are set to vest on the date of the company's next annual stockholder meeting.

Traws Pharma (NASDAQ: TRAW) has deferred its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) following a negative review from the UK's MHRA, delaying clinical evaluation of its lead antiviral candidate. Despite this setback, the company maintains its commitment to influenza antivirals, citing TXM's efficacy in animal models and a cash runway extending to Q1 2027. Traws Pharma is actively advancing backup influenza candidates designed to avoid regulatory concerns while preserving similar antiviral and pharmacokinetic characteristics.

Traws Pharma announced that its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) has been deferred due to a negative review from the UK's MHRA. Despite this setback, the company's Chief Science Officer noted TXM's potential for emergency use in bird flu outbreaks, and the company is advancing alternative influenza antiviral candidates. Traws Pharma remains committed to developing long-acting influenza antivirals, extending its cash runway to Q1 2027 to support these efforts.

Traws Pharma announced a regulatory setback for its influenza program, deferring a planned Phase 2a human trial of tivoxavir marboxil (TXM) due to a negative review by the UK MHRA. Despite this, the company emphasized TXM's efficacy in animal models and its commitment to developing long-acting influenza antivirals, advancing backup candidates. Traws Pharma also confirmed a cash runway extending into Q1 2027 to support ongoing development.

Arista Networks (NYSE: ANET) stock rose over 4% on Friday following a bullish report from Morgan Stanley analyst Meta Marshall, who raised her price target to $190 from $180 while maintaining an "overweight" rating. Marshall believes Arista Networks is well-positioned to benefit as artificial intelligence (AI) implementations move into the inference stage, requiring next-generation equipment and increased processing power. The company is seen as a high-value supplier in cloud networking, poised to capitalize on the scaling of AI technologies.

General Motors (GM) is currently facing conflicting valuation views, stemming from the tension between its current cash flows, significant investments in electric vehicles, and ambitious software plans. The company's main challenge involves financing its transition to EVs and software while simultaneously protecting its traditional vehicle business. GM is categorized as a consumer stock, with its performance closely tied to consumer spending and evolving mobility needs.

Amgen is defending its rare disease drug, Tavneos, against an FDA proposal to withdraw its approval due to safety concerns and alleged clinical trial data manipulation. The pharmaceutical company has requested a hearing with the FDA and commissioned an independent review of the pivotal trial data from the Duke Clinical Research Institute. Tavneos, acquired by Amgen in 2022, treats ANCA-associated vasculitis and will remain available to patients during the review process, despite growing concerns about liver toxicity and the drug's clinical trial integrity raised during securities fraud litigation against ChemoCentryx, its original developer.

Republic Services is experiencing significant delays in trash pickup in Vienna Township, with residents reporting collections being weeks late. The article notes that visual evidence in the neighborhoods confirms these delays.

Sempra's LNG division is undergoing a change in ownership and management, which could lead to a more aggressive LNG export strategy for the California-based utility. The restructuring suggests a potential shift away from a currently risk-averse approach in its LNG ventures.